Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9732281 | 1.00 | CHRNA7 (0.46) | CHRNA7ACHETDP1ALOX5LMNA | |
| SCHEMBL3693273 | 0.84 | CHRNA7 (0.55) | CHRNA7ACHETDP1ALOX5LMNA | |
| SCHEMBL11938485 | 0.84 | CHRNA7 (0.55) | CHRNA7ACHETDP1ALOX5LMNA | |
| SCHEMBL11938483 | 0.84 | CHRNA7 (0.55) | CHRNA7ACHETDP1ALOX5LMNA | |
| SCHEMBL17014700 | 0.80 | TYR (0.41) | LMNAALDH1A1ADRA2AADRA2CHIF1A | |
| SCHEMBL28037840 | 0.79 | ACHE (0.44) | CHRNA7ACHETDP1ALOX5LMNA | |
| SCHEMBL23232284 | 0.77 | IDO1 (0.41) | LMNAALDH1A1SMN1; SMN2CES2CES1 | |
| SCHEMBL7073627 | 0.77 | ESR1 (0.48) | TDP1LMNAALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL801235 | 0.77 | CHRNA7 (0.48) | CHRNA7ACHETDP1ALOX5LMNA | |
| SCHEMBL801000 | 0.77 | CHRNA7 (0.48) | CHRNA7ACHETDP1ALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2884982-B1 | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9353066-B2 | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | CHRNA7 4769/4885ACHE 3813/4885TDP1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.